Hosted on MSN1mon
MSD halts Winrevair trial due to success of previous studyThe company confirmed that it has decided to end the placebo-controlled HYPERION trial (NCT04811092) examining Winrevair (sotatercept-csrk) after results from the ZENITH trial (NCT04896008 ...
According to the release, clinicians can expect to see HYPERION study results in 2025. Merck announces pivotal phase 3 ZENITH trial evaluating WINREVAIR (sotatercept-csrk) met primary endpoint at ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo (both in combination with ...
In addition to STELLAR, MSD is running the phase 3 HYPERION trial of sotatercept in newly diagnosed intermediate- and high-risk PAH patients, seeking to move it up the treatment pathway ...
Meanwhile, MSD is running the phase 3 HYPERION trial of sotatercept in newly diagnosed intermediate- and high-risk PAH patients, seeking to move it up the treatment pathway, as well as the phase 2 ...
Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension (PAH) drug, Winrevair (sotatercept), for a more advanced version of ...
announced today the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback